» Articles » PMID: 30290304

MiR-7 Suppresses Tumor Progression by Directly Targeting MAP3K9 in Pancreatic Cancer

Overview
Publisher Cell Press
Date 2018 Oct 6
PMID 30290304
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Extensive research has suggested that miR-7 plays a critical role in cancer progression. However, the biological function of miR-7 in pancreatic cancer (PC) progression is poorly understood. Therefore, in the present study, we investigated the function of miR-7 and its molecular mechanism in PC progression. We used multiple methods, such as MTT, FACS, Transwell assay, RT-PCR, western blotting, and transfection to investigate the role of miR-7 in PC cells. We found that miR-7 suppressed cell growth, migration, and invasion but induced apoptosis in PC cells. Moreover, overexpression of miR-7 repressed tumor growth in mice, suggesting that miR-7 could exert its tumor-suppressive function in PC. Mechanistically, we validated that MAP3K9 is a direct target of miR-7, which significantly enhanced PC cell proliferation and inhibited cell apoptosis partly through activation of the MEK/ERK pathway and NF-κB pathway. Moreover, rescue experiments also showed that miR-7 suppressed PC cell proliferation and induced PC cell apoptosis by directly targeting MAP3K9, leading to inhibition of the MEK/ERK and NF-κB pathways. Taken together, these results suggest that miR-7/MAP3K9 is critically involved in PC progression and that miR-7 may be a potential target for PC treatment.

Citing Articles

Circ_DLG1 facilitates cell proliferation and metastasis of esophageal squamous cell carcinoma via upregulating MAP3K9.

Wang H, Wu Y, Yang Y, Pang Y, Hu H, Gou Y Esophagus. 2025; .

PMID: 40042790 DOI: 10.1007/s10388-025-01115-w.


LncRNA SLC16A1-AS1 participates in the initiation and progression of colorectal cancer by regulating MAP3K9 expression through targeting miR-515-5p.

Xu W, Bi S, Xing M Am J Cancer Res. 2024; 14(11):5539-5550.

PMID: 39659936 PMC: 11626282. DOI: 10.62347/ABOI7514.


Extracellular Vesicular miRNA in Pancreatic Cancer: From Lab to Therapy.

Tiwari P, Shanmugam P, Karn V, Gupta S, Mishra R, Rustagi S Cancers (Basel). 2024; 16(12).

PMID: 38927885 PMC: 11201547. DOI: 10.3390/cancers16122179.


IL21 inhibits miR-361-5p to promote MAP3K9 and further aggravate the progression of shoulder arthritis.

Hao K, Lin P, Li J, Hu J, Wang J, Li F Aging (Albany NY). 2024; 16(9):7915-7927.

PMID: 38728237 PMC: 11132011. DOI: 10.18632/aging.205793.


MicroRNAs in Pancreatic Cancer: Advances in Biomarker Discovery and Therapeutic Implications.

Madadjim R, An T, Cui J Int J Mol Sci. 2024; 25(7).

PMID: 38612727 PMC: 11011772. DOI: 10.3390/ijms25073914.


References
1.
Martini M, Russo M, Lamba S, Vitiello E, Crowley E, Sassi F . Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. Cancer Res. 2013; 73(6):1912-21. DOI: 10.1158/0008-5472.CAN-12-3074. View

2.
Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang W . MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer. PLoS One. 2014; 9(5):e96718. PMC: 4016102. DOI: 10.1371/journal.pone.0096718. View

3.
Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

4.
Akamatsu M, Makino N, Ikeda Y, Matsuda A, Ito M, Kakizaki Y . Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis. PLoS One. 2016; 11(7):e0158669. PMC: 4933352. DOI: 10.1371/journal.pone.0158669. View

5.
Gallo K, Johnson G . Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol. 2002; 3(9):663-72. DOI: 10.1038/nrm906. View